Trial reportScience (New York, N.Y.)2022
Vaccination induces HIV broadly neutralizing antibody precursors in humans.
Open access · greenAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph
Trial report in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 192 papers.
0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed
17.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
192 citing papers in PubMed, 257 citations in OpenAlex.
- Trial
- Candidate correlates of protection in the HVTN505 HIV-1 vaccine efficacy trial identified by positive-unlabeled learning.PLoS computational biology · 2025Trial
- Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.Science (New York, N.Y.) · 2025Trial
- Precise targeting of HIV broadly neutralizing antibody precursors in humans.Science (New York, N.Y.) · 2025Trial
- Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.Science translational medicine · 2025Trial
- Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.Cell reports · 2025Trial
- The Failure of AIDS Vaccine Efficacy Trials: Where to Go from Here.Journal of virology · 2023Trial
- Article
- Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.medRxiv : the preprint server for health sciences · 2026Article
- A stealth delivery platform for B cell-based immunity.Molecular therapy. Nucleic acids · 2026Article
- Overcoming immunogenic gaps in malaria subunit vaccines by broadening CSP regions targeted.The Journal of experimental medicine · 2026Article
- Advancements of mRNA-lipid nanoparticle links to gene editing and immune responses.Journal, genetic engineering & biotechnology · 2026Review
- Learned young: HIV-1 germline-targeting vaccination in infants.Current opinion in HIV and AIDS · 2026Review
- Review
- Article
- Structure-based design of stable recombinant hepatitis C virus E1E2 heterodimers.Nature communications · 2026Article
- Rapid boosting increases germinal center responses to sequential vaccines.Nature immunology · 2026Article
- VRC01-CLASS PRECURSOR FREQUENCY IN AN AFRICAN POPULATION IS INFLUENCED BY IGHV1-2 ALLELIC COMPOSITION AND NOT MALARIA EXPOSURE.Research square · 2026Article
- mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- What's Hot in HIV in 2025-A Basic and Translational Science Review From IDWeek 2025.The Journal of infectious diseases · 2026Review
132 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
57 authors at 9 institutions in 2 countries.
David J Leggat *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-4019-7170
Kristen W Cohen *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-8901-9941
Jordan R Willis *IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-0135-5263
William J Fulp *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Allan C deCamp *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-1404-4322
Oleksandr KalyuzhniyIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-5273-1951
Christopher A CottrellIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-3364-3083
Sergey MenisIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Greg FinakVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-4341-9090
Lamar Ballweber-FlemingVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-6180-5545
Abhinaya SrikanthVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Jason R PlylerVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Torben SchiffnerIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-6772-8870
Alessia LiguoriIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-8606-574X
Farhad RahamanIAVI, New York, NY 10004, USA.ORCID 0000-0003-4069-4580
Angela LombardoIAVI, New York, NY 10004, USA.ORCID 0000-0003-0182-133X
Vincent PhiliponisIAVI, New York, NY 10004, USA.
Rachael E WhaleyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0001-5411-7333
Aaron SeeseVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-5877-6229
Joshua BrandVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-4578-4860
Alexis M RuppelVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wesley HoylandVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-0747-0625
Nicole L YatesCenter for Human Systems Immunology, Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University, Durham, NC 27701, USA.ORCID 0000-0003-2678-1311
LaTonya D WilliamsCenter for Human Systems Immunology, Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University, Durham, NC 27701, USA.ORCID 0000-0001-8064-8533
Kelli GreeneDuke University Medical Center, Durham, NC 27701, USA.
Hongmei GaoDuke University Medical Center, Durham, NC 27701, USA.ORCID 0000-0002-2468-8589
Celia R MahoneyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Martin M CorcoranDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Alberto CagigiVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-3567-9514
Alison TaylorVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-2319-8481
David M BrownThe Foundation for the National Institutes of Health, North Bethesda, MD 20852, USA.ORCID 0000-0003-4463-8316
David R AmbrozakVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Troy SincombIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-4556-649X
Xiaozhen HuIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-3890-0533
Ryan TingleIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-2874-7010
Erik GeorgesonIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-5137-4625
Saman EskandarzadehIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-0671-0770
Nushin AlaviIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-3848-6280
Danny LuIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-2340-3377
Tina-Marie MullenIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-6150-8084
Michael KubitzIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Bettina GroschelIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-3127-5448
Janine MaenzaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-3992-4193
Orpheus KolokythasDepartment of Radiology, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0001-6707-9962
Nadia KhatiDepartment of Radiology, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA.
Jeffrey BethonyDepartment of Microbiology, Immunology and Tropical Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA.
Shane CrottyCenter for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-6484-6262
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-7448-7040
Gunilla B Karlsson HedestamDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID 0000-0001-7255-9047
Georgia D TomarasCenter for Human Systems Immunology, Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University, Durham, NC 27701, USA.ORCID 0000-0001-8076-1931
David MontefioriDuke University Medical Center, Durham, NC 27701, USA.ORCID 0000-0003-0856-6319
David DiemertDepartment of Microbiology, Immunology and Tropical Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA.ORCID 0000-0002-2789-0512
Richard A KoupVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-3090-7282
Dagna S LauferIAVI, New York, NY 10004, USA.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-2276-7117
Adrian B McDermottVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-0616-9117
William R SchiefIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-1120-0150
Scripps Research Institute · USNational Institutes of Health · USFred Hutch Cancer Center · USDuke University · USInternational AIDS Vaccine Initiative · USUniversity of Washington · USGeorge Washington University · USFoundation for the National Institutes of Health · USKarolinska Institutet · SE
Funding
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MIdentification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MHVTN Laboratory ProgramU01AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MCELRATH, MARGARET JULIANA · 2006 to 2010
$82.6MSWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Italo Mocchetti · 2015 to 2026
$29.6MSystems Biology CoreU19AI128914 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Margaret Juliana McElrath, KENNETH D STUART · 2017 to 2026
$29.5MSeattle Vaccine Trials UnitUM1AI069481 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Rachel Ann Bender Ignacio, Margaret Juliana McElrath · 2012 to 2026
$24.4MStructure/function studies of immunogen recognition by anti-HIV antibody b12P01AI094419 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI STAMATATOS, LEONIDAS · 2011 to 2015
$10.6MNIAID NIH HHS P01 AI094419NIAID NIH HHS U01 AI068618NIAID NIH HHS U19 AI128914NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI069481NIAID NIH HHS UM1 AI144462
Abstract
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial, the HIV vaccine-priming candidate eOD-GT8 60mer adjuvanted with AS01
Indexed as
AIDS VaccinesBroadly Neutralizing AntibodiesGerm CellsHIV AntibodiesHIV InfectionsImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsAdjuvants, ImmunologicAdultB-LymphocytesFemaleHumansMaleMutationVaccinationAdjuvants, ImmunologicAIDS VaccinesBroadly Neutralizing AntibodiesHIV AntibodiesImmunoglobulin Heavy ChainsImmunoglobulin Light Chains
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.